|A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer|
|Reviewer: Heather Jones, MD|
|The Abramson Cancer Center of the University of Pennsylvania|
Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, et al.
The classic paper by Rosell et al addresses one of the more vexing issues in the treatment of lung cancer patients (ranking among many); the management of stage III disease in non-small cell lung cancer. In part, the controversy exists because many retrospective publications and small randomized trials have addressed a wide range of stage III subsets with inconsistent pathologic documentation of the nodal status. However, the critical question differs for two distinct groups within stage III patients:
1. In the group with minimal, nonbulky disease, initial surgical resection has been the standard of care. These subsets include T3N0 or N1, and non-enlarged N2 on CT scan. The debate here is whether preoperative chemotherapy with or without radiation therapy improves survival over surgery alone.
2. For the group with bulky disease, chemoradiation is the current standard of care. These tumors include bulky N2 disease on CT scan, N3 disease, and T4 primaries. The debate in this group is whether surgical resection after induction chemoradiotherapy improves outcome over chemoradiation alone.
The Rosell et al paper falls into the former group.The study design
This phase III trial addressing the effects of preoperative chemotherapy on the survival of patients with stage IIIA non-small cell lug cancer shows that preoperative chemotherapy increased the median survival of these patients.
As noted earlier, this strongly positive trial in favor of induction chemotherapy has generated much discussion and debate. One must consider when reviewing the Rosell et. al. trial that only 60 patients were a enrolled. We know that N2 disease was not required for eligibility and mediastinoscopy was not mandated if the mediastinum was negative on CT scan. In the study, 25 of 30 patients in the chemotherapy arm (83%) had mediastinoscopy, whereas only 19 of 30 patients (63%) in the surgery alone arm had mediastinoscopy. This leaves open the question of under staging of the surgery alone patients. One also wonders why the surgery arm did so poorly in this trial; despite the fact that 37% of them had N0 or N1 disease. This trial closed early due to the marked survival differences noted. However, it is not clear whether the early stopping rules for this very small trial accounted for the strong potential influence of even slight imbalances in substage or molecular prognosis between the arms.